As surgical volumes climb and advanced technology becomes more common in the operating room, Chelsea Hospital is expanding ...

The Radioligand Therapy Market is projected to reach US$13 billion by 2030, growing at an estimated rate of 5%. Key drivers of this growth include the rising incidence of cancers such as prostate ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.

The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced. Dubbed IsoPSA, the in vitro diagnostic kit is ...